Senior/Principal Scientist, Bioinformatics at Remix Therapeutics

Watertown, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

PhD in Computational Biology, Bioinformatics, or Computer Science
5+ years experience in industry
Background in cancer biology preferred
Knowledge and experience with publicly available datasets (TCGA, GTEx, DepMap etc)
Outstanding bioinformatics programming skills in at least one language relevant to data analysis such as Python or R
Proficient with Linux environment and scripting language, such as bash
Proficient in cloud computing (e.g. AWS)
Ability to effectively communicate methodologies and results with colleagues, including bench scientists, research management, and project team leaders
Strong problem-solving and troubleshooting skills
Ability to work in a dynamic and fast-paced environment independently and efficiently
Knowledge of RNA-biology and splicing is preferred
Authorized to legally work in the US
Hybrid role: 3 days on-site, 2 days off-site

Responsibilities

Perform in silico analysis from various sequencing technologies to extract biological insights in compound mechanism of action, therapeutic strategy, and disease biology
Analyze multi-omic proprietary and publicly available data such as TCGA and DepMap and combine data sets to extract biological insight
Collaborate with bench scientists to design and execute experiments for the development of a comprehensive pre-clinical data package in oncology
Develop intuitive data visualizations, presentations, and communicate results to the broader company
Participate and thrive in a culture of effective collaboration between experimental and computational scientists

Skills

Bioinformatics

Computational Biology

Next-Generation Sequencing

NGS

Genomic Data Analysis

RNA Processing

Biomarker Identification

Oncology

Molecular Data Analysis

Data Mining

Integrative Data Analysis

Remix Therapeutics

Develops mRNA-based treatments for rare diseases

About Remix Therapeutics

Remix Therapeutics focuses on creating treatments for rare and difficult diseases, particularly targeting rare cancers and genetic disorders. Their main product, REM 422, is an oral small molecule that works by degrading messenger RNA (mRNA), which can stop the production of harmful proteins linked to these diseases. Currently, REM 422 is undergoing Phase 1 clinical trials for Adenoid Cystic Carcinoma and Acute Myeloid Leukemia, and it has received Orphan Drug Designation from the FDA, which offers benefits for drugs treating rare conditions. Unlike many competitors, Remix Therapeutics emphasizes a strong research and development approach, funding their work through grants and partnerships, with the goal of bringing new medicines to patients inspired by personal experiences with serious illnesses.

Cambridge, MassachusettsHeadquarters

2018Year Founded

$205.2MTotal Funding

GROWTH_EQUITY_VCCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Risks

Potential competition from other RNA-targeting biotech companies.

High costs and lengthy clinical trials may strain financial resources.

Regulatory hurdles could delay RNA-targeting drug approvals.

Differentiation

Remix uses REMaster platform to modulate RNA processing for disease treatment.

REM 422 is a first-in-class MYB mRNA degrader for cancer treatment.

FDA granted Orphan Drug Designation to REM 422 for rare diseases.

Upsides

Collaboration with Roche could yield up to $1 billion in milestone payments.

Recent $90 million financing boosts R&D and expansion efforts.

REM 422 shows promising preclinical results in AML and ACC treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free